gfs202a
Cancer Cachexia
Genfleet Therapeutics (Shanghai) Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Cancer Cachexia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
mt-102 Akamis Bio | Phase 2 | B |
GLUCOSE, ANHYDROUS CONKO-Studiengruppe | Phase 2 | B |
TEONANACATL Psyence Australia Pty Ltd | Phase 2 | CCC |
ngm120 NGM Biopharmaceuticals, Inc | Phase 2 | CCC |
jmt203 Shanghai JMT-Bio Inc. | Phase 1/2 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →